Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Share News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.125
Bid: 5.00
Ask: 5.25
Change: 0.125 (2.50%)
Spread: 0.25 (5.00%)
Open: 5.00
High: 5.125
Low: 4.875
Prev. Close: 5.00
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: BAT falls on sales miss; Entain hit by MGM remark

Thu, 09th Feb 2023 09:13

(Alliance News) - Stock prices in London opened higher on Thursday, as investors digested a mixed set of UK company earnings.

The FTSE 100 index opened up 46.46 points, 0.6%, at 7,931.63. The FTSE 250 was 32.18 points, 0.2%, at 20,335.99, and the AIM All-Share was up just 0.1 of a point at 883.32.

The Cboe UK 100 was up 0.6% at 793.36, the Cboe UK 250 down 0.1% at 17,737.05, and the Cboe Small Companies was up 0.1% at 14,173.52.

In European equities on Thursday, the CAC 40 in Paris was up 1.1%, while the DAX 40 in Frankfurt was 1.2% higher.

Europe's largest economy saw inflation speed up slightly at the beginning of the year, according to preliminary figures.

Destatis said consumer prices in Germany rose 1.0% in January from the month before, reversing a 0.8% monthly decline in December. Annual inflation ticked up slightly to 8.7% from 8.6% at the end of 2022.

In Zurich, Credit Suisse fell 5.9%. The troubled Swiss lender posting an annual net loss of CHF7.29 billion, widening several-fold from CHF1.65 billion in 2021. It was the firm's biggest annual loss since the global financial crisis.

Net revenue plunged 34% to CHF14.92 billion from CHF22.70 billion.

Credit Suisse said its 2022 results were "significantly affected by the challenging macro and geopolitical environment with market uncertainty and client risk aversion", affecting client activity across all of its conditions.

Equities in New York had struggled on Wednesday. The Dow Jones Industrial Average closed down 0.6%, the S&P 500 down 1.1% and the Nasdaq Composite down 1.7%.

This came in the wake of several hawkish comments from Federal Reserve officials, stoking fears of persisted high interest rates and potential further hikes.

In comments reported by Bloomberg, Fed Vice Chair John Williams advocated for a "sufficiently restrictive stance of policy", adding that interest rates were "barely into restrictive territory".

"We're going to need to maintain that for a few years to make sure we get inflation to 2%, and then eventually over time we'll get interest rates presumably back to more normal levels," Williams said.

Fed Governor Christopher Waller added: "It might be a long fight, with interest rates higher for longer than some are currently expecting."

Meanwhile, Minneapolis Fed President Neel Kashkari warned there was "not yet much evidence, in my judgment, that the rate hikes that we've done so far are having much effect on the labour market".

Despite the hawkish rhetoric, the dollar was softer in early trade.

Sterling was quoted at USD1.2127, higher than USD1.2084 at the London equities close on Wednesday. The euro traded at USD1.0757, higher than USD1.0734. Against the yen, the dollar was quoted at JPY130.99, down from JPY131.29.

In the FTSE 100, Asia-focused bank Standard Chartered was the top performer, up 7.6%, while gambling operator Entain shed 11%.

In an earnings call on Wednesday, US casino operator MGM Resorts International confirmed it is no longer considering a takeover of Entain. "The simple answer on Entain is no; we've moved on," said MGM CEO Bill Hornbuckle.

Entain had rebuffed a takeover bid from MGM back in 2021. The two firms operate the BetMGM joint-venture together in the US.

AstraZeneca rose 4.1%, as the pharmaceutical firm swung to an annual profit.

Astra said total revenue in 2022 rose by 19% to USD44.35 billion from USD37.42 billion a year before, or by 24% at constant currency. Growth came from all therapy areas, as well as the addition of Alexion.

It swung to a pretax profit of USD2.50 billion from a loss of USD265 million, while core earnings per share jumped 26% to USD6.66. The pharmaceutical maker saw a weaker fourth quarter, however, as revenue fell by 7% to USD11.21 billion and core EPS fell by 17% to USD1.38. The lower revenue in the quarter was partly due to the decline in Vaxzevria, Astra said. Revenue excluding Vaxzevria rose 17%.

Looking ahead, Astra expects revenue in 2023 to grow at low-to-mid single-digit percentages at constant currency, or by low double-digit percentages excluding Covid-19 medicines. Core EPS is expected to see high single-digit to low double-digit growth.

Shore Capital said Astra's fourth-quarter EPS beat consensus. While Astra's forward guidance was in line with expectations, it "might disappoint" investors, the broker said.

British American Tobacco was down 4.1%. BAT reported a marginal rise in profit for 2022, as the cigarette maker navigated an "increasingly challenging" economic environment, but it noted that momentum in New Category was "strong".

In 2022, revenue grew 7.7% to GBP27.65 billion from GBP25.68 billion, despite lower volumes. The figure was below Vuma-cited market consensus of USD28.02 billion.

Cigarettes and tobacco heating products volumes fell by 4.2%. Pretax profit was up just 1.7% to GBP9.32 billion in 2022 from GBP9.16 billion in 2021.

It improved its total dividend by 1.0% to 217.80 pence from 215.60p a year earlier.

Looking ahead to 2023, BAT expects global tobacco industry volume to fall by around 2%. It expects mid-single figure constant currency adjusted earnings per share growth, which will be weighted towards the second half.

Unilever added 0.6%

The consumer goods firm said annual turnover rose 15% year-on-year to EUR60.07 billion from EUR52.44 billion, as pretax profit rose 21% to EUR10.34 billion from EUR8.56 billion. Underlying sales growth was 9.0%, driven by price growth, given that volumes fell 2.1%. In 2023, Unilever expects to deliver strong underlying sales growth.

Underlying price growth is expected to remain high, with volumes to fall in the first half, but said it is "too early to say" whether volumes will see positive growth in the second half.

Unilever expects 2023 underlying sales growth to be at least in the upper half of a 3% to 5% range.

"Despite sharp rises in material costs, we have prioritised stepping up our brand and marketing investment," said CEO Alan Jope.

According to interactive investor's Richard Hunter, the increased marketing spend shows Unilever "recognises the importance of keeping its brands in the mind of consumers". This is "despite price increases which run the risk of alienating cost-conscious shoppers".

In the FTSE 250, cybersecurity AI firm Darktrace rose 4.5%, as it closed its "largest deal-to-date".

The "multi-million dollar, multi-year" contract was signed with an unnamed "major" provider of critical infrastructure services.

Watches of Switzerland shed 5.7% in early trade.

The luxury watch firm reported double-digit growth in its financial third quarter ended January 29, as revenue rose 17% year-on-year to GBP407 million from GBP348 million. This was driven by luxury watches, "where demand continues to exceed supply".

For the whole of financial 2023, Watches expects to bring in revenue of GBP1.50 billion to GBP1.55 billion, with adjusted earnings before interest and tax to be between GBP163 million to GBP175 million. The guidance is on a pre-IFRS 16 basis, with a constant exchange rate applied to the fourth quarter. CEO Brian Duffy reports the firm's expansion into Europe is seeing "positive" early trading.

On AIM, Genedrive surged 34%.

The molecular diagnostics company said the UK's National Institute for Health & Care Excellence has preliminarily recommended its antiobiotic-induced hearing loss test for use in the National Health Service.

NICE's final guidance will follow a public consultation period, which will close on February 21.

In Asia on Thursday, the Nikkei 225 index closed down 0.1%. In China, the Shanghai Composite rose 1.2%, and the Hang Seng index in Hong Kong added 1.6%. The S&P/ASX 200 in Sydney closed down 0.5%.

Gold was quoted at USD1,884.81 an ounce early Thursday, higher than USD1,878.10 on Wednesday. Brent oil was trading at USD85.27 a barrel, edging up from USD84.01.

In the economic calendar, the US will publish its weekly unemployment insurance claims report at 1330 GMT.

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
24 Apr 2024 17:26

Genedrive enters clinical trial deal in US for MT-RNR1 US approval

(Alliance News) - Genedrive PLC on Wednesday said it has entered into a clinical trial agreement to support clinical studies to progress the regulatory approval of its MT-RNR1 product.

Read more
3 Apr 2024 16:54

LONDON MARKET CLOSE: FTSE 100 up thanks to US economic data

(Alliance News) - Stock prices in London closed mostly higher on Wednesday, after some data from the US reinforced the interest rate cut trajectory across the Atlantic.

Read more
3 Apr 2024 13:54

Genedrive shares jump on NICE test recommendation

(Sharecast News) - Genedrive shares were surging on Wednesday, after it received a significant endorsement from the UK's National Institute for Health and Care Excellence (NICE) regarding its 'CYP2C19-ID' test.

Read more
3 Apr 2024 11:49

Genedrive shares surge as UK's NICE backs test for ischaemic stroke

(Alliance News) - Genedrive PLC on Wednesday praised the National Health Service's work on strokes and mini strokes as a test by the company received a recommendation from the UK's National Institute for Health & Care Excellence.

Read more
3 Apr 2024 10:47

AIM WINNERS & LOSERS: UK NICE backs Genedrive test; Corero renews deal

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
28 Mar 2024 14:35

EARNINGS AND TRADING: 888 advances US exit; Arrow ups reserve estimate

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
15 Mar 2024 14:27

Genedrive receives R&D tax credit, plans fundraise

(Sharecast News) - Point-of-care pharmacogenetic testing company Genedrive announced the receipt of a research and development tax credit totalling £0.8m on Friday, taking its unaudited cash balances to £1.2m.

Read more
15 Mar 2024 13:50

Genedrive down as plans equity raise despite GBP800,000 tax credit

(Alliance News) - Genedrive PLC shares fell on Friday, after it said it has received a GBP800,000 research and development tax credit.

Read more
19 Feb 2024 18:57

TRADING UPDATES: Coro seals sale terms, Powerhouse makes good progress

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
19 Feb 2024 10:56

Genedrive set to apply for NICE EVA funding

(Sharecast News) - Genedrive shares rose on Monday, on the launch of the NICE early value assessment (EVA) evidence generation funding call, backed by the National Institute for Health and Care Research (NIHR).

Read more
19 Feb 2024 07:49

LONDON BRIEFING: MoneySupermarket credits Insurance for growth in 2023

(Alliance News) - Stocks in London are set to fall at Monday's open, as concerns over US inflation trends curb risk appetite, and damp hopes of interest rate cuts from the Federal Reserve.

Read more
2 Jan 2024 14:39

Genedrive confirms £0.6m equity prepayment drawdown

(Sharecast News) - Genedrive confirmed a planned £0.6m drawdown as part of its £5m equity prepayment facility on Tuesday, which it initially disclosed on 31 March 2023.

Read more
2 Jan 2024 10:57

IN BRIEF: Genedrive draws down GBP600,000 on prepayment facility

Genedrive PLC - Manchester, England-based molecular diagnostics company - Draws down GBP600,000 on its GBP5 million equity prepayment facility. In March last year, Genedrive agreed the GBP5 million equity prepayment facility with Riverfort Global Opportunities PCC Ltd. At the time it said that proceeds would be used towards the commercialisation of the antibiotic-induced hearing loss test, Genedrive MT-RNR1 ID Kit, and enhancing the Genedrive platform as well as providing additional working capital.

Read more
22 Dec 2023 15:50

UK shareholder meetings calendar - next 7 days

Monday 25 December 
no events scheduled 
Tuesday 26 December 
no events scheduled 
Wednesday 27 December 
Tremor International LtdAGM
Thursday 28 December 
ADVFN PLCAGM
Altona Rare Earths PLCAGM
Beximco Pharmaceuticals LtdAGM
Global Petroleum LtdAGM
Visum Technologies PLCAGM
Friday 29 December 
Apollon Formularies PLCAGM
Eco Atlantic Oil & Gas LtdAGM
Genedrive PLCAGM
Goldplat PLCAGM
Lansdowne Oil & Gas PLCGM re capital raise
Marula Mining PLCAGM
Microsaic Systems PLCGM re fundraise
Online Blockchain PLCAGM
Secure Property Development & Investment PLCAGM
SkinBioTherapeutics PLCAGM
Tetragon Financial Group LtdAGM
Woodbois LtdAGM
Zambeef Products PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
20 Dec 2023 13:57

Genedrive gets first product orders from several countries

(Sharecast News) - Point-of-care pharmacogenetic testing company Genedrive has received its first orders for Genedrive MT-RNR1 products from several countries, it announced on Wednesday, including France, Austria, Greece, Saudi Arabia, Turkey, and the Netherlands.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.